H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30
Annovis Bio Is Maintained at Buy by EF Hutton
Annovis Bio Analyst Ratings
H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $26
Buy Rating on Annovis Bio Amid Progress in PD and AD Drug Development
Maxim Group Maintains Annovis Bio(ANVS.US) With Hold Rating
Annovis Bio (ANVS) Receives a Hold From Maxim Group
Annovis Bio Price Target Maintained With a $21.00/Share by EF Hutton
Annovis Bio Analyst Ratings
Buy Rating Affirmed for Annovis Bio Amid Promising Buntanetap Trials and Stable Financials
H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30
Annovis Bio Analyst Ratings
EF Hutton Initiates Annovis Bio(ANVS.US) With Buy Rating, Announces Target Price $21
Maxim Group Keeps Their Hold Rating on Annovis Bio (ANVS)
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Sensei Biotherapeutics (SNSE) and Annovis Bio (ANVS)
Buy Rating Affirmed: Annovis Bio's Buntanetap and Dulaglutide Combo Show Promise for Alzheimer's Breakthrough
Buy Rating Affirmed for Annovis Bio Amidst Promising Drug Developments and Strategic Team Expansion
Annovis Bio Analyst Ratings
Buy Rating Affirmed: Promising Buntanetap Phase 3 Results and Increased Approval Probability Boost Annovis Bio's Price Target